Established in 1819, ESCP Europe is the oldest business school in the world. Its mission is to develop the next generation of transnational business leaders, preparing them to embrace the opportunities offered by cultural diversity. Through a combination of innovative pedagogy, cross-campus programs and a research-active faculty, ESCP Europe is an essential contributor to the development of the transnational management culture so essential in today’s global business environment. In relation to the healthcare and pharmaceutical industry, the university offers select executive level programs, including a Specialized Master in Bio-pharmaceutical Management, as well as a part-time Executive Specialized Master in Healthcare Management. The aim of the Specialized Master in Bio-pharmaceutical Management in particular is to prepare future managers of pharmaceutical, medical consulting and biotechnology companies for immediate insertion in a professional environment that is currently undergoing dramatic changes. The program taught at the university’s Paris campus and London campus offers practical training that combines knowledge acquisition with the development of decision-making skills. The University’s 45,000-strong alumni network counts members from 200 nationalities. Together with its long-standing relationships with national and multinational companies, this network allows ESCP Europe to provide unique career opportunities on an international scale.
The dynamic Director of ESCP Europe’s Master in Biopharmaceutical Management talks about being the reference higher education institution for programs catering to the biopharma sector, plans for more international visibility,…
Vincent Pont, president of Laboratoire Arrow, explains the company’s history, its collaboration with Aurobindo, the Indian generic pharmaceuticals group, the company’s unique positioning as a leader in the generic hospital…
Bertrand de Lavenne, general manager of Mylan France, explains how the affiliate is positioned within the group’s operations and how the Mylan strategy is to be a key actor in…
Christophe Lala, general manager of western Europe for GE Healthcare offers an overview of the current dynamics impacting the French healthcare landscape – namely a shift in structure around care…
Martine Claret of Horus Pharma – a family-owned ophthalmology pharmaceutical company established in 2003 and based in Nice – discusses the highly regulated and competitive ophthalmology market, the company’s remarkable…
Faten Hidri, VP for Higher Education & Research in the Paris Region (Ile de France), discusses the vital role of academic research and the life sciences in her region and…
Pascal Girin, CEO of BALT, shares how his rich career in neurovascular medical technology helped him to transform the company from a small R&D pure player into an international market…
Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to…
Bertrand Sohier, VP and general manager business and administration of Parexel France discusses the latest trends impacting the clinical research environment of the country, gives insight on the strategies the…
Michel Spagnol, chairman and CEO of Novasep, a robust French CDMO, shares his insights on the key global trends that are shaping today’s CMDO sector – particularly the emerging significance…
France is rediscovering its mojo. After a period of relative stagnation, the country’s highly strategic USD 65 billion healthcare and life sciences market is once again an attractive investment proposition.…
Jean-Marc Grognet, general manager of Genopole, France’s leading biotechnology cluster, explains the organization’s unique triangular structure with the corner points of the cluster being higher education, research, and industry. Grognet…
Jean-Louis Anspach, general manager of Teva France, elaborates on the affiliate’s transitional restructuring period as they make a turnaround effort in the face of group-wide challenges. Anspach goes on to…
See our Cookie Privacy Policy Here
